首页> 外国专利> Differential immunocytochemical diagnosis of cancer using anti-bodies of antisera against hCG-beta

Differential immunocytochemical diagnosis of cancer using anti-bodies of antisera against hCG-beta

机译:使用针对hCG-beta的抗血清抗体进行癌症的鉴别免疫组化诊断

摘要

An immunocytochemical analytic assay for hCGβ, in a fixed sample of tissues or cells, which uniformly and reliably demonstrates the presence of hCGβ in malignant cells of all kinds. Underlying this new method is the realization that it was the omnipresent formalin fixative used in prior art immunocytochemical hCGβ assays which irretrievably destroyed the hCGβ antigens in oncologic samples and prevented their detection--as well as the realization that not one of the various known unmasking techniques had been able to revive them. The present method includes as an essential step the selection of a non-formalin fixative for use in fixing the tissue or cellular sample to be analyzed, as well as provision for staining and counterstaining to enable positive morphological classification of certain noncancerous cells known to produce hCGβ. The present protocol also reflects an underlying new appreciation that because hCGβ can be detected in malignant cells of all malignant neoplasm(s), the use of the present immunocytochemical method plus particular morphological classification of noncancer cells can positively identify malignancy in cell or tissue samples 99.9% if not 100% of the time.
机译:在固定的组织或细胞样品中进行hCGβ的免疫细胞化学分析,可均匀可靠地证明各种恶性细胞中均存在hCGβ。该新方法的基础是认识到它是现有技术免疫细胞化学hCGβ分析中使用的无所不在的福尔马林固定剂,它无法挽回地破坏了肿瘤样品中的hCGβ抗原并阻止了它们的检测-以及认识到不是各种已知的非掩盖技术之一能够使他们复活。本方法包括作为必需步骤的选择用于固定待分析的组织或细胞样品的非福尔马林固定剂,以及提供染色和复染色以使已知可产生hCGβ的某些非癌细胞进行形态学分类的准备工作。 。本协议还反映出一种潜在的新认识,因为可以在所有恶性肿瘤的恶性细胞中检测到hCGβ,因此使用本免疫细胞化学方法加上非癌细胞的特定形态学分类可以肯定地识别细胞或组织样品中的恶性肿瘤99.9 %,如果不是100%的时间。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号